The CD24 antigen discriminates between pre-B and B cells in human bone marrow
- PMID: 1700990
The CD24 antigen discriminates between pre-B and B cells in human bone marrow
Abstract
When bone marrow (BM) lymphoid cells from 12 adult healthy donors were labeled by CD24 antibodies and analyzed by flow cytometry, two positive populations of cells were demonstrated in each sample (by a separated bimodal specific immunofluorescence). One population had intermediate CD24-Ag density (termed CD24+ cells) whereas the other had high CD24-Ag density (termed CD24(2+) cells). CD24+ cells represented 5.8 +/- 2.7% of the total lymphoid BM cells and CD24(2+) cells 5.6 +/- 2.5%. Using dual fluorescence analysis on eight samples, all CD24+ cells expressed the CD21 and CD37 mature B cell Ag and also surface IgM (sIgM), but this population lacked CD10 Ag. These cells also expressed CD19 Ag, and at a higher density than CD24(2+) cells. They were also positive for HLA-DR Ag. Conversely, CD24(2+) cells were shown to be early cells of the B cell lineage. While all the CD24(2+) cells were HLA-DR+ and CD19+, 64 +/- 16% of them expressed CD20 Ag (at a lower density than CD24+ cells), 65 +/- 21% CD10 Ag, and 22 +/- 8% were positive for cytoplasmic mu-chains (c mu). None of these cells expressed the CD21 and CD37 mature B cell Ag or sIgM. Additional experiments on four different healthy donors demonstrated that 30 +/- 9% of the CD24(2+) cells expressed the CD34 Ag and that the CD24+ cells did not express it. Thus, the CD24 Ag permits discrimination between two populations of the B cell lineage present in adult BM: 1) A CD24(2+) cell population including "pre" pre-B cells (HLA-DR+, CD19+, CD10+/-, CD20-, CD21-, CD34+, CD37-, c mu-), "intermediate" pre-B cells (HLA-DR+, CD19+, CD10+, CD20+, CD21-, CD34-, CD37-, c mu-), and "true" pre-B cells (HLA-DR+, CD19+, CD10+, CD20+, CD21-, CD34-, CD37-, c mu+). 2) A CD24+ cell population including B cells of the standard phenotype (HLA-DR+, CD19+, CD10-, CD20+, CD21+, CD34-, CD37+, c mu-, sIgM+).
Similar articles
-
[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].Ai Zheng. 2007 Apr;26(4):418-22. Ai Zheng. 2007. PMID: 17430665 Chinese.
-
No expansion of the pre-B and B-cell compartments in the bone marrow of patients with multiple myeloma.Cancer Res. 1991 Jun 15;51(12):3224-8. Cancer Res. 1991. PMID: 1904006
-
Multiparameter flow cytometric analysis of human fetal bone marrow B cells.Leukemia. 1990 May;4(5):354-8. Leukemia. 1990. PMID: 1697009
-
Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules.Hematol Oncol Clin North Am. 1992 Apr;6(2):297-322. Hematol Oncol Clin North Am. 1992. PMID: 1533857 Review.
-
The CD19/CD21 signal transduction complex of B lymphocytes.Immunol Today. 1994 Sep;15(9):437-42. doi: 10.1016/0167-5699(94)90274-7. Immunol Today. 1994. PMID: 7524521 Review.
Cited by
-
Somatically diversified and proliferating transitional B cells: implications for peripheral B cell homeostasis.J Immunol. 2011 Jun 1;186(11):6437-44. doi: 10.4049/jimmunol.1003897. Epub 2011 Apr 27. J Immunol. 2011. PMID: 21525392 Free PMC article.
-
Site-Specific DC Surface Signatures Influence CD4+ T Cell Co-stimulation and Lung-Homing.Front Immunol. 2019 Jul 18;10:1650. doi: 10.3389/fimmu.2019.01650. eCollection 2019. Front Immunol. 2019. PMID: 31396211 Free PMC article.
-
Cell Surface Glycoprotein CD24 Marks Bone Marrow-Derived Human Mesenchymal Stem/Stromal Cells with Reduced Proliferative and Differentiation Capacity In Vitro.Stem Cells Dev. 2021 Mar;30(6):325-336. doi: 10.1089/scd.2021.0027. Stem Cells Dev. 2021. PMID: 33593128 Free PMC article.
-
Normal pre-B cells express a receptor complex of mu heavy chains and surrogate light-chain proteins.Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6284-8. doi: 10.1073/pnas.88.14.6284. Proc Natl Acad Sci U S A. 1991. PMID: 1906177 Free PMC article.
-
CD24 Expression and B Cell Maturation Shows a Novel Link With Energy Metabolism: Potential Implications for Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.Front Immunol. 2018 Oct 22;9:2421. doi: 10.3389/fimmu.2018.02421. eCollection 2018. Front Immunol. 2018. PMID: 30405620 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials